Skip to content

Efficacy Evaluation of Products Against Long Wavelength Ultraviolet A1 and Visible Light Induced Biological Effects

Efficacy Evaluation of Products Against Long Wavelength Ultraviolet A1 and Visible Light Induced Biological Effects

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04181476
Enrollment
12
Registered
2019-11-29
Start date
2019-11-05
Completion date
2022-06-30
Last updated
2022-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sun Damaged Skin

Brief summary

The purpose of this study is to evaluate the efficacy of topical products in providing protection against the visible light and ultraviolet A1 (UVA1) part of sunlight. Ultraviolet radiation and visible light are both components of sunlight that reach the earth. It is important to test these topical products against visible light and UVA1 because our current sunscreens may not protect against these very well.

Interventions

DRUGSunscreening Agents

Four different sunscreens

Sponsors

L'Oreal
CollaboratorINDUSTRY
Henry Ford Health System
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patient age 18 and older * Patients Fitzpatrick skin phototype (SPT) III-IV with normal skin health * Patient able to understand requirements of the study and risks involved

Exclusion criteria

* A recent history of vitiligo, melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation * A history of a relevant skin condition on any part of the patient's body (e.g. atopic dermatitis, eczema, vitiligo, sun burn, etc. * A known history of photodermatoses * A known history of photosensitivity disorders * A known history of melanoma or non-melanoma skin cancers

Design outcomes

Primary

MeasureTime frameDescription
Change in Investigator's Global Assessment (IGA)through study completion, an average of 1 weekAssesses erythema and pigmentation
Change in Colorimetrythrough study completion, an average of 1 weekMeasures erythema and pigmentation
Change in Diffuse Reflectance Spectroscopythrough study completion, an average of 1 weekMeasures erythema and pigmentation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026